Quintrio
Home

INDUSTRIAL ORGANIC CHEMICALS

Codexis, Inc.

CDXS

Codexis Inc is a biotechnology company engaged in providing enzyme-based technology solutions to improve pharmaceutical manufacturing processes. The company operates through two key business areas: the ECO Synthesis manufacturing platform and small molecule pharma biocatalysis. The ECO Synthesis platform focuses on developing enzymatic processes for the large-scale manufacture of RNA interference therapeutics, while the biocatalysis business utilizes engineered enzymes to enhance efficiency, yield, and sustainability in small molecule drug manufacturing. Geographically, it derives maximum revenue from the Americas.

Last trade $1.06
Day change -$0.005 (-0.47%)
Day range $1.01 – $1.12
Volume 691,370
Market cap $116M

Open XNAS

Fundamentals

Key company ratios and reported financial statements.

Source: Massive.com

Key ratios

Valuation

Market capitalization
$116.17M
Price / earnings
—
Price / book
2.27×
Price / sales
1.32×
EV / sales
1.45×
EV / EBITDA
-16.54×

Profitability

Earnings per share
-$0.18
Return on assets
-13.34%
Return on equity
-37.54%
Dividend yield
0%

Liquidity and leverage

Debt / equity
0.81×
Current ratio
2.81×
Quick ratio
2.75×
Cash ratio
0.86×

Cash flow

Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$12.14M

Ratios use trailing-twelve-month financials and market data as of Nov 16, 2026.

Financial statements

Income and cash flow amounts are for the period; balance sheets are point-in-time snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are displayed when available.

Income statement for CDXS, quarterly periods
Line itemQ3 FY2026 Sep 30, 2026Q2 FY2026 Jun 30, 2026Q1 FY2026 Mar 31, 2026Q4 FY2025 Dec 31, 2025Q3 FY2025 Sep 30, 2025Q2 FY2025 Jun 30, 2025Q1 FY2025 Mar 31, 2025Q4 FY2024 Dec 31, 2024
Revenue$19.26M$14.92M$15.25M$38.92M$8.6M$15.33M$7.54M$21.46M
Cost of revenue$4.01M$3.51M$2.06M$2.04M$2.47M$2.1M$2.73M$3.65M
Gross profit$15.25M$11.4M$13.18M$36.87M$6.14M$13.23M$4.81M$17.81M
Selling, general and administrative$10.1M$10.93M$9.78M$11.19M$11.22M$12.32M$12.36M$13.05M
Research and development$12.59M$11.71M$11.45M$11.72M$13.87M$13.78M$12.94M$12.1M
Total operating expenses$22.68M$22.63M$21.23M$26.31M$25.09M$26.09M$25.3M$25.15M
Operating income-$7.44M-$11.23M-$8.04M$10.56M-$18.95M-$12.86M-$20.49M-$7.34M
Interest expense$0$0$0$0$0$0$0$0
Income before taxes-$8.12M-$12M-$8.67M$9.62M-$19.61M-$13.26M-$20.68M-$10.37M
Income taxes$9K$10K$36K$18K$8K$10K$11K$3K
Net income-$8.13M-$12.01M-$8.7M$9.6M-$19.62M-$13.27M-$20.69M-$10.38M
Net income attributable to common shareholders-$8.13M-$12.01M-$8.7M$9.6M-$19.62M-$13.27M-$20.69M-$10.38M
EBITDA-$6.3M-$10.02M-$6.76M$15.32M-$17.59M-$11.52M-$19.29M-$6.13M
Basic earnings per share-$0.08-$0.13-$0.10$0.11-$0.22-$0.16-$0.25-$0.13
Diluted earnings per share-$0.08-$0.13-$0.10$0.11-$0.22-$0.16-$0.25-$0.13

Recent news

Company coverage with links to the original publishers.

Publication times in UTC
Zacks Investment Research

Codexis (CDXS) Reports Q3 Loss, Beats Revenue Estimates

Codexis (CDXS) reported a quarterly loss of $0.08 per share, beating consensus estimates of $0.09 loss, with revenues of $19.26 million exceeding expectations by 4.16%. Despite the earnings beat and consistent outperformance over four quarters, the stock has declined 40.1% year-to-date versus the S&P 500's 11.3% gain. The company holds a Zacks Rank #3 (Hold) rating with mixed estimate revisions, suggesting near-term performance in line with the market.

Zacks Investment Research

Opus Genetics, Inc. (IRD) Reports Q3 Loss, Lags Revenue Estimates

Opus Genetics reported a quarterly loss of $0.18 per share, missing the consensus estimate of $0.14 by 28.57%, and posted revenues of $1.14 million, falling 43.8% short of expectations. The company has underperformed consensus estimates in 3 of the last 4 quarters. Despite a 109% year-to-date gain, the stock received a Zacks Rank #3 (Hold) rating, suggesting near-term performance in line with the market.

GlobeNewswire Inc.

Codexis Enters into $60 Million Term Loan Facility with Trinity Capital

Codexis, Inc. announced a $60 million senior secured term loan agreement with Trinity Capital Inc. to refinance existing debt and provide capital flexibility for advancing its ECO Synthesis Manufacturing Platform for siRNA therapeutic manufacturing. The new facility offers 48 months of interest-only payments followed by a 12-month amortization period beginning November 2030, with post-closing outstanding debt of $42.5 million.

GlobeNewswire Inc.

Codexis Advances ECO Synthesis Toward Adoption Readiness with Quality at Scale and Expanded siRNA Manufacturing Capabilities

Codexis presented data at TIDES Europe 2026 demonstrating its ECO Synthesis Manufacturing Platform achieved over 90% product quality at 100-gram scale while nearly halving cycle time. The company also showcased new capabilities in tissue-targeting functionality and biological evidence that defined siRNA stereochemistry produced 3-4 fold increased potency compared to traditional chemical synthesis methods, advancing the platform toward industrialization and adoption readiness.

Zacks Investment Research

Arcturus Therapeutics (ARCT) Reports Q3 Loss, Beats Revenue Estimates

Arcturus Therapeutics (ARCT) reported a quarterly loss of $0.26 per share, beating consensus estimates of $0.60 loss by 56.67%, with revenues of $18.3 million exceeding estimates by 116.10%. The stock has gained 77.3% year-to-date, significantly outperforming the S&P 500's 12.3% gain. However, the company holds a Zacks Rank #3 (Hold) rating with mixed estimate revisions, suggesting near-term performance in line with the market.

Dividends

Declared distributions and recorded event dates. Forecasts are not shown.

Updated daily

No declared upcoming dividend found.

No prior dividend records found.

Stock splits

Historical share-structure events and their execution dates.

Updated daily

No stock split records found.